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Abstract
Background:  Originating from Africa, India, and the Middle East, frankincense oil has been
important both socially and economically as an ingredient in incense and perfumes for thousands
of years. Frankincense oil is prepared from aromatic hardened gum resins obtained by tapping
Boswellia trees. One of the main components of frankincense oil is boswellic acid, a component
known to have anti-neoplastic properties. The goal of this study was to evaluate frankincense oil
for its anti-tumor activity and signaling pathways in bladder cancer cells.
Methods: Frankincense oil-induced cell viability was investigated in human bladder cancer J82 cells
and immortalized normal bladder urothelial UROtsa cells. Temporal regulation of frankincense oil-
activated gene expression in bladder cancer cells was identified by microarray and bioinformatics
analysis.
Results: Within a range of concentration, frankincense oil suppressed cell viability in bladder
transitional carcinoma J82 cells but not in UROtsa cells. Comprehensive gene expression analysis
confirmed that frankincense oil activates genes that are responsible for cell cycle arrest, cell growth
suppression, and apoptosis in J82 cells. However, frankincense oil-induced cell death in J82 cells did
not result in DNA fragmentation, a hallmark of apoptosis.
Conclusion: Frankincense oil appears to distinguish cancerous from normal bladder cells and
suppress cancer cell viability. Microarray and bioinformatics analysis proposed multiple pathways
that can be activated by frankincense oil to induce bladder cancer cell death. Frankincense oil might
represent an alternative intravesical agent for bladder cancer treatment.
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Background
Frankincense resin is obtained from trees of the genus
Boswellia (family Burseraceae). Incisions are made in the
trunks of the trees to produce exuded gum, which appears
as milk like resin. The resin hardens into orange-brown
gum resin known as frankincense. There are numerous
species and varieties of frankincense trees, including
Boswellia serrata in India, Boswellia carteri in East Africa and
China, Boswellia frereana in Somalia, and Boswellia sacra in
Arabia, each producing a slightly different type of resin.
Differences in soil and climate create more diversity in the
resins, even within the same species. The aroma from
these resins is valued for its presumed healing properties
and superior qualities for religious rituals since the time of
the ancient Egyptians [1], and has been used in incense,
fumigants, and as a fixative in perfumes.
Frankincense resin has been considered throughout the
ages to have a wealth of health supporting properties. The
resins of Boswellia carteri and Boswellia serrata have been
used for the treatment of rheumatoid arthritis and other
inflammatory diseases [2] such as Crohn's disease [3] in
traditional medicine of many countries. The anti-inflam-
matory activity has been attribute to the resin's ability in
regulating immune cytokines production [4] and leuko-
cyte infiltration [5,6]. Boswellia serrata extract also exhibits
anti-bacterial and anti-fungal activities [7]. Additionally,
extracts from Boswellia species gum resins might possess
anti-cancer activities, based on their anti-proliferative and
pro-apoptotic activities in rat astrocytoma cell lines [8]
and in human leukemia cell lines [9], as well as their anti-
carcinogenic activity in chemically induced mouse skin
cancer models [10]. Clinically, extract from the resin
reduces the peritumoral edema in glioblastoma patients
[8] and reverses multiple brain metastases in a breast can-
cer patient [11]. These results suggest that frankincense
resin contains active ingredients that modulate important
biological activities.
In search of the active medicinal ingredients of frankin-
cense resins, Chevrier et al. reported that ethanol extract of
Boswellia carteri resin comprises 7 boswellic acids [4]. Aki-
hisa et al. reported that methanol extract of Boswellia cart-
eri  resin consists of 15 triterpene acids, including
boswellic acids, and 2 cembrane-type diterpenes [12]. 11-
keto-β-boswellic acid, the most potent anti-inflammatory
component of the resin, selectively blocks leukotriene
biosynthesis through inhibiting 5-lipoxygenase activity in
rat neutrophilic granulocytes [13] and provides protective
effects in a chemically induced mouse ulcerative colitis
model [14]. Boswellic acids also prevent endotoxin/galac-
tosamine-induced hepatitis in mice [15]. In addition,
boswellic acids have been shown to possess anti-cancer
activities through their cytostatic and apoptotic effects in
multiple human cancer cell lines including meningioma
cells [16], leukemia cells [17], hepatoma cells [18],
melanoma cells, fibrosarcoma cells [19], and colon cancer
cells [20].
Frankincense oil, an extract prepared by steam distillation
from frankincense gum resin, is one of the most com-
monly used oils in aromatherapy practices. There has
been considerable work done on the composition of
frankincense oil from different species and commercial
brands; and the constituents of frankincense oil differ
according to the climate, harvest conditions, and geo-
graphical sources of frankincense resins [21]. Due to the
contribution of boswellic acids, it is possible that frankin-
cense oil also holds anti-cancer and anti-neoplastic prop-
erties. In this study, we demonstrated that a commercial
source of frankincense oil can discriminate bladder cancer
J82 cells from normal bladder urothelial UROtsa cells and
suppress cancer cell viability. Based on gene expression
analysis, frankincense oil activated several anti-prolifera-
tive and pro-apoptotic pathways that might be responsi-
ble for frankincense oil-induced cell death in J82 cells.
Methods
Reagents and chemicals
Cell culture medium [MEM and DMEM/F-12 (1:1)], fetal
bovine serum (FBS), MEM vitamin solution, non-essen-
tial amino acids, epidermal growth factor (EGF), insulin-
transferrin-sodium selenite (ITS) media supplement,
sodium pyruvate, and penicillin-streptomycin were pur-
chased from Invitrogen (Grand Island, NY). Frankincense
oil containing 1,200 mg/ml frankincense gum resin was
obtained from Young Living Essential Oils (Lehi, UT).
XTT cell proliferation assay and in situ cell death detection
kits were obtained from Roche (Indianapolis, IN). Trypan
blue was purchased from Sigma (St. Louis, MO). RNeasy®
Mini Kit was obtained from Qiagen (Valencia, CA).
Human bladder cell lines
Bladder transitional cell carcinoma J82 was obtained from
ATCC (HTB-1; Manassas, VA). The J82 cell line was
derived from a poorly differentiated, invasive human
transitional cell bladder carcinoma (stage 3) [22]. J82 cells
were maintained in growth medium consisting of MEM
supplemented with 10% FBS, 0.1 mM non-essential
amino acids, 1 mM sodium pyruvate, 2% MEM vitamin
solution, 100 units/ml penicillin, and 100 μg/ml strepto-
mycin. The UROtsa cell line was originally isolated from
a primary culture of normal human urothelium and
immortalized with a construct containing the SV40 large
T antigen [23]. UROtsa cells were cultured in DMEM/F12
supplemented with 10 ng/ml EGF, 1× ITS media supple-
ment, 100 units/ml penicillin, and 100 μg/ml streptomy-
cin. Cells were maintained in a humidified cell incubator
at 37°C and 5% CO2 and passaged every 3–4 days or
when cells reached about 80% confluence.BMC Complementary and Alternative Medicine 2009, 9:6 http://www.biomedcentral.com/1472-6882/9/6
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Cell viability analysis
To determine number of viable cells following frankin-
cense oil treatment, J82 and UROtsa cells were seeded in
96-well tissue culture plates at the density of 1 × 104 cells/
mm2  in 100 μl growth medium. Following overnight
incubation for adherence, 100 μl cell growth media or var-
ying dilutions of frankincense oil (at1:600 to 1:4,000 final
concentration) in their growth media were added to each
well in triplicate to make a total of 200 μl. Cell viability
was determined at the time of treatment and at 24 hours
following frankincense oil exposure using the XTT cell
proliferation assay kit. Briefly, at the time of assay, 100 μl
growth media were removed from each well, and an aliq-
uot of 50 μl XTT labeling mixture was added back to each
well. Reactions were performed at 37°C for 4 hours.
Absorbance was obtained by reading the plates at 450 nm
wavelength using μQuant microplate reader (Bio-Tek;
Winooski, VT). Absorbance values obtained at 24 hours
for untreated and frankincense oil-treated cells were nor-
malized to the values obtained at the time of treatment to
calculate fold changes in cell survival.
Trypan blue exclusion was also included to determine cell
viability following frankincense oil treatment. Briefly, J82
and UROtsa cells were seeded in 24-well tissue culture
plates at the same density as used in XTT assay in 500 μl
growth media. Following adherence, cells received either
500 μl of growth medium or varying dilutions of frankin-
cense oil in each well. At 3 hours after frankincense oil
treatment, the culture medium was collected to save the
non-adherent cells; and the remaining cells were
trypsinized and combined with the cells harvested from
the culture medium. The cells were collected by centrifu-
gation, and re-suspended with 200 μl phosphate buffered
saline (PBS). Then, an aliquot (20 μl) of the cell suspen-
sion was mixed with the same volume of 0.4% (w/v)
trypan blue solution. The cells were counted using a
hemocytometer to determine the numbers of blue cells
(non-viable) and bright cells (viable). Cell viability was
expressed as the percentage of trypan blue positive cells
compared to the total number of cells.
RNA extraction and quality evaluation
Total RNA was isolated from J82 cells for microarray anal-
ysis. Briefly, 2 × 105 J82 cells were seeded in 60 mm tissue
culture plates, cultured overnight for adherence, and
either left untreated or treated with 1:1,000 dilutions of
frankincense oil in growth medium. Total RNA was iso-
lated at 0 hours (no treatment) and at 0.5, 1, 2, and 3
hours after stimulation using the RNeasy® Mini total RNA
isolation kit based on manufacture's recommendations
(Qiagen; Valencia, CA). Total RNA concentration was
determined with a nanodrop scanning spectrophotome-
ter, and then qualitatively assessed for degradation using
the ratio of 28:18s rRNA by a capillary gel electrophoresis
system (Agilent 2100 Bioanalyzer, Agilent Technologies;
Santa Clara CA).
RNA labeling, microarray hybridization, and scanning
A total of 250 ng of RNA from each time point was labeled
using the Illumina Total Prep RNA Amplification Kit fol-
lowing manufacturer's directions (Ambion; Austin. TX).
Briefly, cDNA was reverse transcribed from RNA after
priming with T7-oligo-dT, and cRNA was synthesized in
vitro  from the T7 promoter while incorporating bioti-
nylated UTP. cRNA was hybridized overnight to Illumina
human Ref-8 version 3 BeadChips containing probes for a
total of 24,526 transcripts. Microarray chips were washed
to high stringency and labeled with streptavidin -Cy3
(Amersham Biosciences; Piscataway, NJ) prior to scanning
on an Illumina BeadArray Reader.
Bioinformatics data analysis
Non-normalized fluorescent intensity of each probe on
the microarray slide was obtained using the DirectHyb
gene expression package in BeadStudio software (Illu-
mina, version 3.1.3). Fluorescent intensity filtering was
performed to remove genes that lacked a minimum rela-
tive fluorescence of 64 units in at least one time point.
Data from the remaining probes were log transformed
and quantile normalized (Matlab). A final filtering was
performed to identify genes with a minimum two-fold
change in normalized expression values between adjacent
time points. Expression data are available on Gene Expres-
sion Omnibus (GEO) with accession number GSE14002.
TUNEL (terminal deoxynucleotidyl transferase dUTP nick 
end labeling) Analysis
TUNEL analysis was performed in J82 cells using an
immunohistochemical (IHC)-like staining procedure as
we reported [24]. Briefly, adherent J83 cells were either
left untreated or treated with 1:1,000 dilution of frankin-
cense oil. At 3 hours after treatment, both non-adherent
and adherent and cells were collected following centrifu-
gation. Cell pellets were fixed in 10% formalin, immersed
in 2% agarose, and subjected to paraffin embedding. The
embedded cell blocks were sectioned, dewaxed, and rehy-
drated. Apoptotic cells were detected using the in situ cell
death detection kit. Following the terminal deoxynucle-
otidyl transferase reaction, fast red substrate was added for
color development. Slides were then washed and sealed
with an aqueous mounting medium.
DNA fragmentation analysis
To determine whether J82 cells undergo DNA fragmenta-
tion following frankincense oil treatment, 2 × 105 J82 and
UROtsa cells were seeded in 60 mm tissue culture plates
in their growth media, incubated overnight for adherence,
and treated with a 1:1,000 dilution of frankincense oil in
growth media. Cells were harvested at 0 (untreated con-BMC Complementary and Alternative Medicine 2009, 9:6 http://www.biomedcentral.com/1472-6882/9/6
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trol), 1, 3, and 6 hours following treatment; and genomic
DNA was prepared and precipitated based on reported
procedures [25]. Quantities of the genomic DNA were
determined spectrophotometrically. Aliquots (10 μg) of
the genomic DNA were separated on a 2% agarose gel;
images of ethidium bromide stained gels were captured by
the Gel Doc 100 system (Bio-Rad, Hercules, CA).
Statistics
The results are expressed as mean ± SEM from four exper-
iments. Comparisons of J82 and UROtsa cell survival fol-
lowing frankincense oil treatment were made using the
one-way analysis of variance (ANOVA) followed by post
hoc Dunnett's test. P < 0.05 was considered statistically
significant.
Results
Frankincense oil-suppressed bladder cell viability
The bladder carcinoma J82 cells presented a density-inde-
pendent growth and grew in soft agar, but were not tum-
origenic in nude mice [26]. The immortalized bladder
urothelial UROtsa cells expressed SV40 large T antigen,
but did not acquire characteristics of neoplastic transfor-
mation, including growth in soft agar or the development
of tumors in nude mice [23]. To determine if frankincense
oil suppresses bladder cell viability, both J82 and UROtsa
cells were subjected to morphological evaluation and cell
viability assessment. J82 cells underwent significant mor-
phological changes, such as detaching from tissue culture
plates and shrinking beginning within 3 hours following
frankincense oil exposure. At 24 hours after treatment, J82
cells completely detached from tissue culture plates
whereas untreated controls remained adherent to the
plates (Figure 1A and 1B). In contrast, UROtsa cells
remained attached to the bottom of plates and did not
show noticeable morphological alterations (Figure 1C
and 1D).
To determine whether frankincense oil affects J82 and
UROtsa cell viability, the number of viable J82 and
UROtsa cells was determined following various dilutions
(1:600 to 1:1,400) of frankincense oil exposure. In
untreated controls, number of viable J82 cells and UROtsa
cells increased 1.62 ± 0.31 and 2.72 ± 0.85 fold at 24
hours following cell seeding, respectively (Figure 2). Both
J82 and UROtsa cells responded to frankincense oil treat-
ment in a dose-dependent manner. J82 cell viability
decreased when cells were treated with increasing concen-
trations of frankincense oil. No viable J82 cells remained
at 24 hours after treatment with 1:1,100 dilution of frank-
incense oil (0.47 ± 0.43). In contrast, UROtsa cell viability
was not significantly affected by the increasing concentra-
tions of frankincense oil until 1:600 dilution was applied
to the cells. When UROtsa cells were treated with 1:600
dilution of frankincense oil, cell viability decreased to
1.29 ± 0.77 fold as compared to untreated cells. No viable
UROtsa cells were detected when the concentration of
frankincense oil concentration increased to 1:400 (data
not shown). Based on the XTT assay, IC50 values (the 50%
inhibitory concentrations of frankincense oil) for J82 and
UROtsa cells were 1:600 and 1:1,250, respectively. Trypan
blue exclusion produced results similar to the XTT assay,
except that J82 and UROtsa cells seem to be more sensi-
tive to frankincense oil treatment at 1:1,300 and 1:600
dilutions, respectively (Figure 2B).
Identification of frankincense oil-activated gene 
expression
To determine the nature of J82 cell death, microarray anal-
ysis was performed. Of the 24,526 gene probes on the
microarray, 8,430 probes had a fluorescent intensity value
of at least twice the background intensity for one or more
time points under evaluation. A total of 122 genes in J82
cells were increased above two-fold in at least two adja-
cent time points by frankincense oil (see Additional file
1). Only 3 of these genes increased within the first 30 min
Morphological changes of bladder carcinoma J82 and bladder  urothelial UROtsa cells following frankincense oil stimulation Figure 1
Morphological changes of bladder carcinoma J82 and 
bladder urothelial UROtsa cells following frankin-
cense oil stimulation. Bladder J82 and UROtsa cells were 
seeded in 96-well tissue culture plates at the concentration 
of 1 × 104 cells/mm2, cultured overnight for adherence, and 
either left untreated or subjected 1:1,000 dilution of frankin-
cense oil stimulation. Images were taken at 24 hours follow-
ing treatments for (A) untreated J82 cells, (B) J82 cells 
treated with frankincense oil, (C) untreated UROtsa cells, 
and (D) UROtsa cells treated with frankincense oil using 
Olympus IX51 inverted microscope. Notice cell shrinkage 
observed in J82 cells following frankincense oil treatment. In 
contrast, UROtsa cells did not experience noticeable mor-
phological alteration following the same concentration of 
frankincense oil exposure.
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[zinc finger protein 57, the small nucleolar RNA C/D box
48, and early growth response 1 gene (EGR1)]. Levels of
EGR1 mRNA increased 5.87-fold within the first 30 min,
and another 2.86-fold over the next 30 min. Another 15
genes increased at least two-fold between 30 and 60 min
after frankincense oil stimulation; and 11 of which con-
tinued to show elevated expression beyond the first hour.
A much larger number of genes increased in expression
between 1 and 2 and between 2 and 3 hours following
frankincense oil exposure.
A total of 47 genes were down-regulated in J82 cells by
frankincense oil (see Additional file 2). Three genes [tubu-
lin gamma 1, vacuolar protein sorting 11 homolog, and
RNA polymerase II (DNA directed) polypeptide K] were
the first to decrease greater than two-fold between 30 and
60 min after frankincense exposure. Another 12 genes
decreased between 1 and 2 hours, and 32 other genes
decreased between 2 and 3 hours. An additional 12 genes
were identified whose levels of expression changed at least
two-fold between two adjacent time points and then
changed in the opposite direction at least two-fold
between the next adjacent time points. These 12 genes
were ankyrin repeat domain 27, chromosome 5 open
reading frame 34, calcineurin binding protein 1,
dodecenoyl-coenzyme A delta isomerase, dynein (axone-
mal, intermediate polypeptide 2), ATG2 [autophagy
related 2 homolog A, N-deacetylase/N-sulfotransferase
(heparan glucosaminyl) 2], oviductal glycoprotein 1,
plexin A3, somatostatin receptor 1, transcriptional variant
1 of rinucleotide repeat containing 5, and zinc finger and
BTB domain containing 11.
Functional grouping of frankincense oil-regulated genes
The gene products that were altered in frankincense oil-
treated bladder carcinoma J82 cells were functionally
grouped according to Gene Ontology classification. Based
on the biological functions, gene products that function
as cytokines, membrane receptors, enzymes (including
kinases, peptidases, and phosphatases), and molecular
transport were identified and listed in Table 1. A complete
list of genes under each classification is provided in Addi-
tional file 3. Frankincense oil-regulated gene products that
function as transcription factors, cell cycle arrest and cell
proliferation, as well as apoptotic factors showed that
frankincense oil induces cell cycle arrest and apoptosis in
J82 cells.
Transcription regulators
Two transcription factors, LOC12629 and EGR1, were
immediately (within 30 min) up-regulated by frankin-
cense oil (Table 2). Another 5 transcription factors,
including ATF3, FOS, FOSB, KLF2, and ZNF234 were up-
regulated within 1 hour and sustained for at least 2 hours
following frankincense oil treatment. Three transcription
factors, KLF4, KLF5, and ZBTB11 were up-regulated by
frankincense oil between 1 and 2 hours post-treatment.
The remaining 11 transcription factors (DDIT3, DEDD2,
DENR, HES1, ID1, JUN, JUNB, SNAPC1, TSC22T1, UBTF,
ZFP36) were considered to be late responders because
their expression was altered after 2 hours of frankincense
oil exposure.
Cell cycle arrest and cell proliferation
Several gene products identified as frankincense oil
responsive genes were negatively associated with regula-
tion of cell proliferation and positively associated with
cell cycle arrest (Table 3). Genes that have been identified
as anti-proliferative genes, including IL8, CLK1, DLG1,
KLF4, NEDD9, CDKN1A, IL1A, IL6, and SNFILK were up-
regulated in frankincense oil-treated J82 cells. In addition,
Bladder cell survival in response to frankincense oil exposure Figure 2
Bladder cell survival in response to frankincense oil 
exposure. Cell viability was determined using (A) a colom-
etric XTT assay at 24 hours and (B) trypan blue exclusion at 
3 hours after frankincense oil stimulation. All experiments 
were prepared in triplicate for XTT assay and duplicate for 
trypan blue exclusion. Data were presented as mean ± stand-
ard error of mean (SEM) from at least 3 independent experi-
ments. * indicates statistical difference between frankincense 
oil-treated J82 cells and UROtsa cells (P < 0.05).
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DDIT3 along with IL8 and CDKNIA being identified to be
responsible for cell cycle arrest were also up-regulated by
frankincense oil. In contrast, H2AFX and HDAC4, genes
that are responsible for DNA repair and cell cycle progres-
sion, were suppressed by frankincense oil. Other anti-pro-
liferative genes, including SSTR1, IL1A, and IL6, were also
up-regulated between 0.5 and 2 hours upon frankincense
oil stimulation.
Apoptosis
Levels of a large number of genes that are responsible for
apoptosis were found to be modulated by frankincense oil
(Figure 3). These genes included CDKN1A, DEDD2, IER3,
IL6, SGK, and TNFAIP3 (up-regulated between 1 and 2
hours and remained up-regulated) as well as GAD45B,
NUDT2, and others (up-regulated between 2 and 3
hours). In addition, the cell survival gene, AXL, was down-
regulated by frankincense oil. However, two anti-apop-
totic genes, GSTP1 and IL1A, were up-regulated. A similar
contradiction was seen with a pro-apoptotic gene, ING4,
being down-regulated.
Frankincense oil-induced cell death
TUNEL analysis was performed to determine whether
frankincense oil treated J82 cells undergo apoptosis.
Frankincense oil treatment resulted in an increased
number of bright red colored TUNEL positive cells as
compared to untreated cells (Figure 4A). Genomic DNA
fragmentation was determined between hours 1 and 6 in
J82 cells following frankincense oil treatment. Agarose gel
electrophoresis results showed that all genomic DNA
remained as large pieces of DNA without forming a small
DNA ladder (Figure 4B). There was no detectable genomic
DNA for J82 cells harvested at 12 hours following frankin-
cense oil treatment (data not shown).
Discussion
Ranging from herbs to acupuncture, alternative medicine
is becoming increasingly popular for managing health-
related issues. In this brief report, we described that frank-
incense oil, with a window of concentration, specifically
suppressed cell viability in human bladder carcinoma J82
cells, but did not affect cell viability in immortalized nor-
Table 1: Functional groups of frankincense oil-regulated genes in bladder cancer J82 cells
Function Gene Symbol Description
Cytokines
CCL2 chemokine (C-C motif) ligand 2
CCL5 chemokine (C-C motif) ligand 5
CMTM8 CKLF-like MARVEL transmembrane domain containing 8
CXCL2 chemokine (C-X-C motif) ligand 2
IL1A interleukin 1, alpha
IL6 interleukin 6 (interferon, beta 2)
IL8 interleukin 8
Enzymes – kinases
ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene)
AXL AXL receptor tyrosine kinase
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CLK1 CDC-like kinase 1
DLG1 discs, large homolog 1 (Drosophila)
FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)
PSTK phosphoseryl-tRNA kinase
SGK1 serum/glucocorticoid regulated kinase 1
SNF1LK SNF1-like kinase
TAOK1 TAO kinase 1
TRIB1 tribbles homolog 1 (Drosophila)
Enzymes – peptidases
RCE1 RCE1 homolog, prenyl protein peptidase (S. cerevisiae)
Enzymes – phosphatases
DUSP10 dual specificity phosphatase 10
DUSP2 dual specificity phosphatase 2
DUSP5 dual specificity phosphatase 5
MTMR6 myotubularin related protein 6
NUDT2 nudix (nucleoside diphosphate linked moiety X)-type motif 2
PPP3R1 protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform
PTPN23 protein tyrosine phosphatase, non-receptor type 23
Membrane Receptors
PLAUR plasminogen activator, urokinase receptor
PLXNA1 plexin A1
PLXNA3 plexin A3
SSTR1 somatostatin receptor 1BMC Complementary and Alternative Medicine 2009, 9:6 http://www.biomedcentral.com/1472-6882/9/6
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mal urothelial UROtsa cells. Frankincense oil suppressed
J82 cell viability may be attributed to the activation of
growth arrest and pro-apoptotic genes. The possibility
that the witnessed differences in cell survival could be due
to the presence of EGF in the media was considered.
Despite this concern, we expected that UROtsa cells' resist-
ance to frankincense oil as compared to J82 cells may not
result from the presence of EGF in their growth medium
based on the following observations: first, a higher con-
centrations of EGF (i.e. 1 μg/ml) had been reported for
apoptosis protection [27], second, UROtsa cells cultured
in EGF-free medium were less sensitivity to frankincense
oil-suppressed cell viability as compared to J82 cells,
although the overall UROtsa cell viability was reduced
(data not shown), and third, four other oils, including
sandalwood oil (Santalum album), balsam fir oil (Abies bal-
samea), palo santo oil (Bursera graveolens), and tsuga oil
(Tsuga canadensis) (Young Living Essential Oils), induced
nearly identical cytotoxicity in both J82 and UROtsa cells
(data not shown).
Commercial frankincense oil was directly applied in our
experimental cell models without modification. It was not
our intention in this preliminary study to dissect the spe-
cific chemical composition of frankincense oil nor deter-
mine its efficacious dosage, since some reports indicated
that total frankincense extract is more potent than pure,
specific boswellic acids [9]. However, a standard assess-
ment between chemical composition of frankincense oil
and its efficacy in tumor suppression will be required in
future clinical trials. In addition, frankincense oil was
directed added to cell culture media in this study without
the inclusion of a carrier; and dose-dependent suppres-
sion in cell viability was observed in both J82 and UROtsa
cells in the absence of any oil carrier. The absence of car-
rier eliminated carrier-dependent effects of frankincense
resin extract as reported by Chevrier et al. [4].
Gene expression analysis was terminated within 3 hours
following frankincense oil treatment, since isolated RNA
quality and quantity were not sufficient for microarray
analysis beyond this time point. We reported a total of
122 up- and 47 down-regulated genes with greater than 2-
fold induction or suppression over the period of 3 hours.
Table 2: Frankincense oil-regulated transcription factors in J82 cells
Time after frankincense oil stimulation (hours)
<0.5 0.5–1 1–2 2–3
Up-regulated LOC126295 (NM_173480.1) * ATF3 (NM_001040619.1) KLF4 (NM_004235.3) DDIT3 (NM_004083.4)
EGR1 (NM_001964.2) FOS (NM_005252.2) KLF5 (NM_001730.3) DEDD2 (NM_133328.2)
FOSB (NM_006732.1) ZBTB11 (NM_014415.1) DENR (NM_003677.3)
KLF2 (NM_016270.2) HES1 (NM_005524.2)
ZNF234 (NM_006630.1) ID1 (NM_181353.1)
JUN (NM_002228.3)
JUNB (NM_002229.2)
SNAPC1 (NM_003082.2)
TSC22D1 (NM_006022.2)
UBTF (NM_014233.1)
ZNF682 (NM_033196.1)
Down-regulated POLR2K (NM_005034.3) ING4 (NM_198287.1) HDAC4 (NM_006037.2)
RAI1 (NM_030665.3)
TAF15 (NM_003487.2)
*GenBank accession number.
Table 3: Frankincense oil-regulated growth inhibitory genes in 
J82 cells
Time after frankincense oil exposure(hours)
Gene Symbol 0 <0.5 0.5–1 1–2 2–3
IL8 26.3 32.6 146.2 693.6 1241.4
CLK1 42.3 56.1 57.9 121.2 203.3
DLG1 48.3 41.2 31.2 71.8 37.2
H2AFX 105.6 103.3 106.6 51.0 96.1
ING4 73.7 63.0 75.3 37.2 43.6
KLF4 89.2 68.8 123.2 326.0 556.9
NEDD9 38.3 34.3 23.8 59.7 56.7
SSTR1 47.4 37.2 28.4 70.3 27.2
CDKN1A 56.3 54.5 95.7 167.4 382.9
DDIT3 346.7 316.0 523.2 735.5 1647.7
HDAC4 64.4 61.7 52.1 68.0 31.5
IL1A 63.4 44.5 72.1 124.5 252.5
IL6 190.5 235.4 337.2 563.8 1326.4
SNF1LK 40.6 38.8 48.9 95.8 286.3
IL8 26.3 32.6 146.2 693.6 1241.4
CLK1 42.3 56.1 57.9 121.2 203.3
DLG1 48.3 41.2 31.2 71.8 37.2
Normalized values of fluorescent intensities are presented. Bold font 
indicates a minimum two-fold change between adjacent time points.BMC Complementary and Alternative Medicine 2009, 9:6 http://www.biomedcentral.com/1472-6882/9/6
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Hierarchical clustering of frankincense oil-regulated apoptosis-related genes in J82 cells Figure 3
Hierarchical clustering of frankincense oil-regulated apoptosis-related genes in J82 cells. The map was obtained 
using Biometric Research Branch (BRB) ArrayTools version 3.4.0 – Beta_2 software http://linus.nci.nih.gov/BRB-Array-
Tools.html after log2 transformation of fluorescence intensities. Each column represents time intervals following frankincense 
oil exposure, and each row represents a gene probe set. The expression levels for individual genes are indicated by green/red 
color indicating an elevated/suppressed level of expression, respectively.
Time after frankincense oil
exposure (hours)BMC Complementary and Alternative Medicine 2009, 9:6 http://www.biomedcentral.com/1472-6882/9/6
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These findings suggested very specific actions of frankin-
cense oil. The genome-wide gene expression analysis sup-
ports patterns of stress, activation of cell cycle arrest,
suppression of cell proliferation, and activation of apop-
totic signaling in frankincense oil-treated J82 cells within
1 hours of stimulation, and some of these processes were
sustained for 3 hours.
Based on the temporal regulation of the genes identified
by microarray and bioinformatics analysis, we proposed
that frankincense oil induces various death pathways in
J82 cells. Waves of transcription factors were regulated by
frankincense oil from between 30 min and 3 hours. EGR1
was one of the few genes that were rapidly up-regulated
within the first 30 min. Although EGR1 has been shown
to be an early gene that is immediately up-regulated in
other systems and is correlated with DNA repair [28], the
mechanism for elevated EGR1 expression by frankincense
oil is unclear. EGR1 has been reported to increase tran-
scription of another transcription factor ATF3 [29]; and
levels of ATF3 were increased in our system between 30
and 60 min after frankincense exposure. ATF3 is induced
by stresses and can bind to DDIT3 [30], which was up-reg-
ulated between 2 and 3 hours in our system. In addition,
DDIT3 responds to DNA damage [31], and is responsible
for cell cycle arrest [32]. Moreover, using the PAINT webt-
ool http://www.dbi.tju.edu/dbi/tools/paint/[33] to
search the TRANSFAC database, we identified EGR1 and
ATF3 binding sequences upstream of multiple apoptosis-
related genes identified in our system. EGR1 can bind 5'-
flanking regions of 5 of the identified apoptosis-related
genes (FGFR1, GADD45B, HES1, RHOB, and TRIB1) that
were up-regulated between 2 and 3 hours. Binding sites
for ATF3 were found in the 5'-flanking regions of 3 apop-
tosis-related genes (FOSB, GEM, and LAMA5) that were
up-regulated between 1 and 2 hours, and 3 additional
genes (HSPA1A, ID1, and JUN) between 2 and 3 hours. By
similar inference, ATF3 may also account for the expres-
sion of 2 down-regulated genes: ING4 (1–2 hours) and
ATG5 (2–3 hours). The sequential expression of these
identified transcription factors may be ultimately respon-
sible for cell cycle arrest, suppressed cell proliferation, and
apoptosis in frankincense oil-treated J82 cells.
Suppressed cell viability and proliferation in frankincense
oil-treated J82 cells was also confirmed by elevated expres-
sion of genes that are responsible for cell cycle arrest and
anti-proliferation. Up-regulated IL8 [34] and CDKN1A
[35] have been shown to be responsible for cell cycle
arrest and suppressed cell proliferation. IL1A is a negative
regulator for cell cycle progression and cell proliferation
[36]; and IL6 has been shown to induce growth arrest
[37]. However, levels of ING4, a molecule that is a nega-
tive regulation of cell proliferation in a human hepatocel-
lular liver carcinoma cell line (HepG2) [38], were up-
regulated in frankincense oil-treated cells. ING4 may
function differently between J82 cells and HepG2 cells; or
ING4 activity is suppressed by a large number of pro-
apoptotic molecules in response to frankincense oil.
Frankincense oil up-regulated several pro-apoptotic
genes, including CDKN1A [39], DEDD2 [40], NUDT2
[41], SGK, TNFAIP3, and IER3 [42]. Elevated expression
(between 0.5 and 2 hours) followed by suppressed expres-
sion (2–3 hours) of a cell survival membrane receptor,
AXL [43], suggests that cells may try to prolong cell sur-
vival following frankincense oil exposure. We also pro-
pose that frankincense oil might activate both extrinsic
and intrinsic death signaling in J82 cells through stress
and death receptors, respectively, to execute apoptosis.
Intrinsic death signaling was suggested by up-regulated
expression of SSRT1, GADD45B, DDIT3, CDKN1A that
have been shown to be required for DNA damage-induced
cell cycle arrest [35,39]. Extrinsic death signaling was
implicated by the up-regulated expression of DEDD2,
which is a death domain receptors and induces apoptosis
[40].
Frankincense oil-induced J82 cell death Figure 4
Frankincense oil-induced J82 cell death. To determine 
whether frankincense oil-induced apoptosis in bladder cancer 
cells, J82 cells were seeded in 60 mm tissue culture plates at 
the concentration of 2 × 105 cells per plate, cultured over-
night for adherence, and either left untreated or treated with 
1:1,000 dilution of frankincense oil. (A) TUNEL analysis was 
performed at 3 hours following treatment. Apoptotic cells 
with damaged DNA were stained positive with a bright red 
color (inserts). (B) DNA fragmentation was determined by 
separating genomic DNA on a 2% agaorse gel; and the gel 
image was captured using Gel Doc 100 system (Bio-Rad, 
Hercules, CA).
M
o
l
e
c
u
l
a
r
 
w
e
i
g
h
t
 
m
a
r
k
e
r
u
n
t
r
e
a
t
e
d Frankincense oil
0    1    3    6  hours
1,000
1,600
2,000
500
5,000
bp
AB
Frankincense oil treated
UntreatedBMC Complementary and Alternative Medicine 2009, 9:6 http://www.biomedcentral.com/1472-6882/9/6
Page 10 of 11
(page number not for citation purposes)
Although the bioinformatics and TUNEL analyses
reported here suggested that frankincense oil induced
apoptosis, rather than necrosis, in J82 cells, frankincense
oil did not cause DNA fragmentation, a hallmark of apop-
tosis, in this bladder cancer cell line. It is possible that
DNA fragmentation occurred between 6 and 12 hours
post frankincense oil treatment. Alternatively, apoptosis
without DNA fragmentation has been reported in several
occasions [44-46]; and frankincense oil-induced J82 cell
death may fit in this category. The detailed molecular and
biological pathways utilized by frankincense oil in induc-
ing bladder cancer cell specific cell death require further
investigation.
This study helps to show that frankincense oil may be
appropriate as an alternative therapy for bladder cancer.
This is the first report demonstrating that frankincense oil
can discriminate between bladder cancer cells and normal
urothelial cells in a cell culture system, and utilizing
microarray technology to identify potential biological
pathways activated by frankincense oil. Our results are
consistent with a news report that frankincense oil specif-
ically targets malignant melanoma but not normal skin
cells in horses http://www.purepeace.com/press/
press_frankincense.pdf. Future studies are required to
determine whether frankincense oil has similar effects on
other bladder cancer cell lines of varying severity such as
RT4, T24, and 5637, followed by in vivo studies using
bladder cancer animal models. In addition, a standard
manufacturing and indication needs to be applied before
the commercial frankincense oil can be used as an alterna-
tive or complementary therapy for treating bladder cancer.
Conclusion
Frankincense oil can discriminate bladder cancer cells and
normal urothelial cells in culture. The oil suppresses cell
survival and induces apoptosis in cultured bladder cancer
cells. Based on this preliminary observation, frankincense
oil may represent an alternative intravesical therapy for
bladder cancer, although more bladder cancer cell lines
and animal models need to be used to confirm current
observations.
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